SYLMAR, Calif - Tuesday, February 24th 2015 [ME NewsWire]
(BUSINESS
WIRE) -- Second Sight Medical Products, Inc. (NASDAQ:EYES) ("Second
Sight" or "the Company"), a developer, manufacturer and marketer of
implantable visual prosthetics to provide functional vision to blind
patients, today announced that Dr. Robert Greenberg, President and Chief
Executive Officer, will present at the 27th Annual ROTH Capital
Partners Conference as follows:
Date:
Monday, March 9, 2015
Time:
8:30 a.m. PST (11:30 a.m. EST)
Location:
The Ritz-Carlton, Laguna Niguel, Track 2, Salon 2
The Company will also host one-on-one meetings throughout the day.
The
presentation will be webcast live at the aforementioned time as well as
archived for 90 days thereafter, via the Company’s website at
www.secondsight.com, under the Investors Section.
About Second Sight
Second
Sight Medical Products, Inc. was founded in 1998 to create a retinal
prosthesis to provide sight to patients blinded from outer retinal
degenerations such as RP. Second Sight's mission is to develop,
manufacture, and market innovative implantable visual prosthetics to
enable blind individuals to achieve greater independence. The Company’s
Argus II retinal prosthesis is approved in the U.S. and Europe. Second
Sight is developing the OrionTM cortical prosthesis to restore some
vision to individuals who are blind due to causes other than preventable
or treatable conditions. The population of people potentially eligible
for the future Orion cortical prosthesis in Germany is about 71,000. The
company’s headquarters are in Sylmar, California, and its European
Headquarters are in Lausanne, Switzerland. For more information, please
visit www.secondsight.com.
Safe Harbor
This press release
contains forward-looking statements within the meaning of Section 27A of
the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange and Exchange Act of 1934, as amended that are
intended to be covered by the “safe harbor” created by those sections.
All statements in this release that are not based on historical fact are
“forward looking statements”. While management has based any forward
looking statements included in this release on its current expectations,
the information on which such expectations were based may change.
Forward-looking statements involve inherent risks and uncertainties
which could cause actual results to differ materially from those in the
forward-looking statements, as a result of various factors including
those risks and uncertainties described in the Risk Factors and in
Management’s Discussion and Analysis of Financial Condition and Results
of Operations sections contained within our final prospectus filed with
the United States Securities and Exchange Commission on November 20,
2014. We urge you to consider those risks and uncertainties in
evaluating our forward-looking statements. We caution readers not to
place undue reliance upon any such forward-looking statements, which
speak only as of the date made. Except as otherwise required by the
federal securities laws, we disclaim any obligation or undertaking to
publicly release any updates or revisions to any forward-looking
statement contained herein (or elsewhere) to reflect any change in our
expectations with regard thereto or any change in events, conditions or
circumstances on which any such statement is based.
Contacts
For Patient Inquiries:
Argus II hotline:
Germany: 0800-184-4321
International: 1 (818) 833-5027
US (toll free): 1 (855) 756-3703
patients@secondsight.com
or
Media Relations:
Pascale Communications, LLC
Audra Friis
917-519-9577
audra@pascalecommunications.com
or
Investor Relations:
Retail Investors:
MZ North America
Matt Hayden, Chairman
949-259-4896
matt.hayden@mzgroup.us
or
Institutional Investors:
In-Site Communications, Inc.
Lisa Wilson, President
212-452-2793
lwilson@insitecony.com
Permalink: http://me-newswire.net/news/13748/en
No comments:
Post a Comment